A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety.
about
Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsEarly erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsErythropoietin for preterm infants with hypoxic ischaemic encephalopathyErythropoietin for term and late preterm infants with hypoxic ischemic encephalopathyEarly erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsPharmacologic neuroprotective strategies in neonatal brain injuryErythropoietin and Neonatal NeuroprotectionKinematic measurement of 12-week head control correlates with 12-month neurodevelopment in preterm infantsMechanisms of cell-cell interaction in oligodendrogenesis and remyelination after strokeDarbepoetin Administration in Term and Preterm NeonatesNeuroprotective potential of erythropoietin in neonates; design of a randomized trial.Outcomes of extremely low birth weight infants given early high-dose erythropoietin.Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.Erythropoietin attenuates loss of potassium chloride co-transporters following prenatal brain injury.Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injuryEffects of transfusions in extremely low birth weight infants: a retrospective study.Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgeryNew antioxidant drugs for neonatal brain injury.The biological basis of injury and neuroprotection in the fetal and neonatal brain.Erythropoietin in stroke therapy: friend or foePharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infantsThe role of cytokines and inflammatory cells in perinatal brain injury.Erythropoietin in brain development and beyond.Postnatal Erythropoietin Mitigates Impaired Cerebral Cortical Development Following Subplate Loss from Prenatal Hypoxia-Ischemia.Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report.Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics.New horizons for newborn brain protection: enhancing endogenous neuroprotectionMultidose optimization simulation of erythropoietin treatment in preterm infants.Erythropoietin as a neuroprotectant for neonatal brain injury: animal models.A randomized, masked study of weekly erythropoietin dosing in preterm infantsTherapeutic potential of erythropoietin and its structural or functional variants in the nervous system.Recombinant human erythropoietin improves neurological outcomes in very preterm infants.Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury.Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia.Neuroprotection in the newborn infantErythropoietin for infants with hypoxic-ischemic encephalopathy.Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury.Intranasal erythropoietin therapy in nervous system disorders.
P2860
Q24195000-2E506060-728F-4204-B540-084BD08BBA29Q24200642-17615234-BC66-4B8B-944D-F23B753572A9Q24202635-5EF6C99D-6D4C-4057-AE49-2558DE4D8019Q24241152-408AE195-6D53-438A-A249-3348A008BA84Q24245418-FABA192D-8F28-41E8-8DAB-7B8E775A0AB2Q26852406-303F0BF3-AE52-4FF7-A742-013ABB8B126AQ27009422-22D3C318-7F4F-4B30-B98B-057D2B5AC956Q27312022-D88CCDA6-7CD6-4AD6-9CA2-568AE478BE9BQ28083718-0A2545C4-6970-428C-8523-74E0661A6087Q28085116-13DE3BD8-502B-4A43-BF7E-AB7894EFA42EQ31071784-9A87C11B-A418-4EB8-BE2D-D90B0541CD40Q33642422-08651700-E707-4243-A02B-3590D692E752Q33713120-835BACF4-20D7-4138-A3B3-C811B115A16CQ33723452-DAB0B7A8-EC42-4864-B5AC-78154F0933A8Q33812116-6D7AA626-2B90-44BC-84E7-631FFC360495Q34053756-6EE45C54-823C-4967-B1B6-22BE07B7E659Q34569855-11A91741-F70A-4A39-BC8C-0DED6E6F8864Q34573299-F61500C5-29A0-4964-AE20-B44E36632036Q34913630-A58256D3-D7B3-4E81-A59F-3D8E943A0375Q35037632-5D1F37B8-E1E0-4C2C-B474-F5A9F1684223Q35201430-C87C7361-13C9-40B7-A2F2-B193445CBFD1Q35548966-B4F50F90-C146-4A7E-A856-065D2D0B75F9Q35565920-7DD7406B-B7D3-4D9C-92FD-C57CF53FF0E4Q35864361-F37211F3-A21C-4CA6-87D0-D82700B85370Q35909929-2828BFF8-9B67-4DCF-82C8-2CFF177CE1A6Q35956626-5DD11F3E-76B6-4F02-B70A-A1C386CE8F8EQ36070895-A78F7EBF-6FAE-4BB1-8DA2-E4DD26307A7AQ36277628-8C2EFA1C-872D-45AA-B50C-CD2A14E15A13Q36374839-F49D3AB0-5B0A-45B2-BA6D-2ED049D6ED06Q36587146-EA76089A-A1E8-40A9-BE16-035F9FC8C6C9Q36624171-680B3D35-D024-4DA2-9542-0EF553F0A26FQ36687686-8BE5E6F0-8A15-4699-8A2D-02D43EC8F90BQ37358669-68D8A7BE-1B1B-47FA-8FAE-4249378A484CQ37375616-E6FB8D62-9945-4D13-84A5-1D8662D306B6Q37396967-5E2FB7BF-EDB7-4377-84A8-EE838F11B0D0Q37416401-8AD2B5F4-780B-4C52-96BF-3AF3472DC16AQ37452432-2C44E872-E5DC-4B82-919B-A7954BBC704BQ37678885-07AFD1A0-A0B0-4ED1-B3F8-EBDE1B92A287Q37724782-FB95E1C8-0DA5-4CC3-9ACA-1DAAC84B08CBQ37818329-B7219FA9-9C33-4504-802D-6040C4C8148A
P2860
A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@en
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@nl
type
label
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@en
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@nl
prefLabel
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@en
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@nl
P2093
P921
P356
P1433
P1476
A phase I/II trial of high-dos ...... : pharmacokinetics and safety.
@en
P2093
Christine A Gleason
Dennis E Mayock
Kelly J Ledbetter
Larry A Bauer
Ronald J McPherson
Sandra E Juul
P304
P356
10.1542/PEDS.2007-2711
P407
P577
2008-08-01T00:00:00Z